Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription 26.05.2025 1 Am J Clin Oncol 1 Am J Hematol 4 Ann Hematol 2 Blood 2 BMC Cancer 1 Bone Marrow Transplant 1 Cancer Lett 4 Leuk Lymphoma 1 Leuk Res 2 Leukemia 1 Oncogene 2 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. HUANG Y, Chen X, Gao C
   Global Trends in Childhood Acute Lymphoblastic Leukemia Burden and Quality of Care Inequalities Across Regions, 1990 to 2021: A Systematic Analysis Using Global Burden of Disease Study 2021 Data.
   Am J Clin Oncol. 2025 May 19. doi: 10.1097/COC.0000000000001210.
   PubMed         Abstract available
   
   

   
   Am J Hematol

2. KADIA TM, Jen WY, Bataller A, Bazinet A, et al
   A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia.
   Am J Hematol. 2025 May 22. doi: 10.1002/ajh.27723.
   PubMed         Abstract available
   
   

   
   Ann Hematol

3. PARK S, Kim HK
   Epidemiologic sequential analysis of pure red blood cell aplasia and T-cell large granular lymphocyte leukemia in Korea.
   Ann Hematol. 2025 May 22. doi: 10.1007/s00277-025-06406.
   PubMed         Abstract available
   
   
4. LIN J, Liu X, Ying S, Zhu Y, et al
   Selective efficacy of venetoclax in unfit patients with acute myeloid leukemia with myelodysplasia-related gene mutations under low-intensity therapy.
   Ann Hematol. 2025 May 22. doi: 10.1007/s00277-025-06399.
   PubMed         Abstract available
   
   
5. GRIMALDI F, Memoli M, Avilia S, Russo R, et al
   Molecular analysis of T-cell Acute Lymphoblastic Leukemia arising after Essential Thrombocythemia foreshadows a distinct clonal route for lymphoid blast crisis in Philadelphia-negative chronic myeloproliferative neoplasm: a case report with literary r
   Ann Hematol. 2025 May 22. doi: 10.1007/s00277-025-06404.
   PubMed         Abstract available
   
   
6. ZHU T, Wang L, Jiang H, Huang S, et al
   Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: results of a single center study.
   Ann Hematol. 2025 May 20. doi: 10.1007/s00277-025-06389.
   PubMed         Abstract available
   
   

   
   Blood

7. JUM'AH H, Viswanatha D
   Classic hairy cell leukemia and concomitant smoldering myeloma.
   Blood. 2025;145:2533.
   PubMed        
   
   
8. BASSAN R, Chiaretti S, Della Starza I, Santoro A, et al
   Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study.
   Blood. 2025;145:2447-2459.
   PubMed         Abstract available
   
   

   
   BMC Cancer

9. LIU Y, Zhang Y, Gao J, Wang L, et al
   Venetoclax and hypomethylating agents versus induction chemotherapy for newly diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis.
   BMC Cancer. 2025;25:894.
   PubMed         Abstract available
   
   
10. ANIS HM, Rakha NM, Kassem DH, Kamal AM, et al
    Emerging roles of ADAM6 and PRSS1 as novel diagnostic/prognostic biomarkers for acute lymphoblastic and myeloid leukemia in adults.
    BMC Cancer. 2025;25:884.
    PubMed         Abstract available
    
    

    
    Bone Marrow Transplant

11. KRAKOW EF, Lee N, Jenkins I, Sala-Torra O, et al
    A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing.
    Bone Marrow Transplant. 2025 May 16. doi: 10.1038/s41409-025-02602.
    PubMed         Abstract available
    
    

    
    Cancer Lett

12. HU LJ, Li CY, Xing T, Wang Y, et al
    N-acetyl-L-cysteine promoted hematopoietic recovery in patients with acute myeloid leukemia after complete remission--A pilot study.
    Cancer Lett. 2025 May 20:217812. doi: 10.1016/j.canlet.2025.217812.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

13. LEVY V, Srivastava T, Gautam R, Swami S, et al
    Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2025 May 23:1-9. doi: 10.1080/10428194.2025.2506501.
    PubMed         Abstract available
    
    
14. MEHTA P, Ngo D, Tinajero J, Agrawal V, et al
    Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia in adults >/=40 years old.
    Leuk Lymphoma. 2025 May 21:1-5. doi: 10.1080/10428194.2025.2506003.
    PubMed        
    
    
15. SHI C, Li Y, Zou X, Yao D, et al
    AP2M1 is a prognostic marker associated with cell cycle arrest and the tumor immune microenvironment in acute myeloid leukemia.
    Leuk Lymphoma. 2025 May 19:1-15. doi: 10.1080/10428194.2025.2504161.
    PubMed         Abstract available
    
    
16. HILL JW, Marvin-Peek J, Sasaki K, Bresser S, et al
    Central nervous system relapse of core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2025 May 19:1-4. doi: 10.1080/10428194.2025.2506505.
    PubMed        
    
    

    
    Leuk Res

17. JOHNSON-ANSAH H, Charbonnier A, Etienne G, Roy L, et al
    Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC.
    Leuk Res. 2025;154:107716.
    PubMed         Abstract available
    
    

    
    Leukemia

18. DEMBITZ V, James SC, Gallipoli P
    Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities.
    Leukemia. 2025 May 22. doi: 10.1038/s41375-025-02645.
    PubMed         Abstract available
    
    
19. AUER F, Morcos MNF, Sipola M, Akhtar I, et al
    Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo.
    Leukemia. 2025 May 20. doi: 10.1038/s41375-025-02626.
    PubMed         Abstract available
    
    

    
    Oncogene

20. XIE Y, Zhao R, Zheng Y, Li Y, et al
    Targeting KPNB1 suppresses AML cells by inhibiting HMGB2 nuclear import.
    Oncogene. 2025;44:1646-1661.
    PubMed         Abstract available
    
    

    
    PLoS One

21. GALLANT R, Reza S, Wiemels JL, Greaves M, et al
    Microbiome and pediatric leukemia, diabetes, and allergies: Systematic review and meta-analysis.
    PLoS One. 2025;20:e0324167.
    PubMed         Abstract available
    
    
22. ILYAS M, Ramzan M, Deriche M, Mahmood K, et al
    An efficient leukemia prediction method using machine learning and deep learning with selected features.
    PLoS One. 2025;20:e0320669.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

23. SAKAMOTO T, Leca J, Zhang X, Meydan C, et al
    Mutant IDH1 cooperates with NPM1c or FLT3(ITD) to drive distinct myeloid diseases and molecular outcomes.
    Proc Natl Acad Sci U S A. 2025;122:e2415779122.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.